AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women

How to Cite

OrthoEvidence. AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women. ACE Report. 2018;7(3):34. Available from: https://myorthoevidence.com/AceReport/Report/10156

Study Type:Randomized Trial

OE Level Evidence:N/A

Journal Level of Evidence:N/A

Abaloparatide Reduced the Risk of Major Nonvertebral Fractures in Postmenopausal Women with Osteoporosis

Contributing Authors:
PD Miller LA Fitzpatrick BH Mitlak G Williams MY Hu G Hattersley SV Bukata

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Access conference website and list of abstracts.

Synopsis

1645 postmenopausal women with osteoporosis were randomized with daily subcutaneous injections or either abaloparatide 80ug or placebo for 18 months. Participants were followed up for the incidence of major non-vertebral fracture over 18 months of treatment. Results demonstrated a significantly lower incidence of major non-vertebral fracture among participants who received abaloparatide compared t...